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Background: The area along the Thai-Cambodian border is considered an epicenter of anti-malarial drug
resistance. Recently, parasite resistance to artemisinin-based therapies has been reported in the area. The
artemisinin resistance containment project was initiated in November 2008, with the aim to limit resistant parasites
and eliminate malaria in this region. This study describes the response to artemisinin-based therapy among
falciparum malaria patients in the area, using data from the malaria surveillance programmed under the
containment project.
Methods: The study was conducted in seven provinces of Thailand along the Thai-Cambodian border. Data of
Plasmodium falciparum-positive patients during January 2009 to December 2011 were obtained from the
electronic malaria information system (eMIS) Web-based reporting system. All P. falciparum cases were followed
for 42 days, as the routine case follow-up protocol. The demographic characteristics of the patients were
described. Statistical analysis was performed to determine the cure rate of the current standard anti-malarial
drug regimen–mefloquine-artesunate combination therapy (MAS). The proportion of patients who remained
parasite-positive at each follow-up day was calculated. In addition, factors related to the delayed parasite clearance
on day-3 post-treatment, were explored.
Results: A total of 1,709 P. falciparum-positive cases were reported during the study period. Almost 70% of
falciparum cases received MAS therapy (n = 1,174). The majority of cases were males, aged between 31 and
50 years. The overall MAS cure rate was >90% over the three-year period. Almost all patients were able to clear
the parasite within 7 to 14 days post-treatment. Approximately 14% of patients undergoing MAS remained
parasite-positive on day-3. Delayed parasite clearance was not significantly associated with patient gender, age,
or citizenship. However, delayed parasite clearance varied across the study area.* Correspondence: tmslw@mahidol.ac.th
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http://www.malariajournal.com/content/11/1/300Conclusion: Anti-malarial drug-resistant parasites should be closely monitored in the area along the Thai-
Cambodian border. Although the MAS cure rate in this study area was above 90%, an increasing trend of treatment
failure has been reported in neighboring parts. Effective malaria surveillance is an important component to monitor
drug-resistance in the malaria containment project.
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Thailand and its neighboring countries have been widely
known as an epicenter of drug-resistant malaria [1].
Chloroquine resistance was first reported in this area in
the 1970s, followed by resistance to other anti-malarial
drugs. Over the past decade, artemisinin-based therapy
became the first-line protocol for the management
of Plasmodium falciparum infections in the Greater
Mekong Sub-region (GMS) [2]. The effectiveness of
artemisinin-based combination therapy has been acknowl-
edged worldwide, contributing to a reduction in the global
malaria burden, especially in areas where P. falciparum
became highly resistant to chloroquine and sulphadoxine-
pyrimethamine [3]. Over the last five years, there has
been increasing public health concern regarding the
emergence of P. falciparum resistance to artemisinins
along the Thai-Cambodian border, possibly spreading to
other regions. Several studies have provided evidence of
resistant hotspots in some western provinces of Cambo-
dia and certain eastern provinces of Thailand, and more
recently there has been serious suspicion of additional
hotspots on the Thai-Myanmar border [4-6]. The
artemisinin-resistance situation remains critical in areas
along the Thai-Cambodian border, where the incidence
of falciparum infection has been declining drastically [7].
Mefloquine-artesunate combination therapy (MAS)
has been used as a first-line regimen in Thailand since
1995, in Cambodia since 2000, and in Myanmar since
2002. Results from in-vivo therapeutic efficacy studies
conducted with MAS in the GMS between 2000 and
2010 show that MAS is still effective, with an adequate
28-day clinical and parasitological response above 90%
in all sentinel sites where studies were conducted, except
in some locations in Cambodia and Thailand where an
increasing treatment failure rate of over 10% was
observed. The treatment failure rate (PCR corrected to
distinguish re-infection from recrudescence) was reach-
ing higher levels with a 42-day follow-up protocol (20%
in Cambodia and 12% in Thailand) [8]. Although the
therapeutic efficacy of artemisinin-based combination
therapy (ACT) has not changed dramatically, recent
clinical and in-vitro studies have suggested that the
delayed parasite clearance time may be a valid, but yet
not perfect indicator of P. falciparum strains’ becoming
less susceptible to the artemisinins, rather than a suddenchange in cure rate [9]. The World Health Organization
(WHO) recommended that the prevalence of patients
remaining parasitaemic on day 3 (72-hours after onset of
ACT) can be used as an indirect (proxy) parasitological
marker of artesunate-resistant strains on the Thai-
Cambodian border [10]. An increase in the proportion
of patients still parasite-positive on day-3 after ACT,
under strict study conditions, may indicate the emer-
gence of suspected falciparum resistance to artemisinin
derivatives in that area [8]. Median parasite clearance
time can be up to 100 hours among patients with sus-
pected artemisinin resistance, compared with less than
48 hours among patients with parasites fully susceptible
to artemisinins [9].
The increasing evidence of emergent artemisinin-
resistant malaria strains in the two countries has trig-
gered regional and global attention, since resistant
strains might spread worldwide, especially to other
highly malaria-endemic countries in Africa, where ACT
is widely used and supported by the international com-
munity [8]. The WHO, as a result, along with develop-
ment partners and countries, released the Global Plan
for Artemisinin Resistance Containment in 2010 aiming
urgently to contain or better eliminate resistant parasites
in the Greater Mekong Sub-region. If successful, the
plan will prevent the further spread of artemisinin-
resistant parasites to other regions and retain the gains
of the previous decade’s efforts [8].
The WHO initiated the anti-malarial drug resistance
containment project in Southeast Asia in November
2008, with extra funding from the Bill & Melinda Gates
Foundation. The ultimate goals of the containment pro-
ject were to identify and keep resistant parasites within
the documented hotspot area (the Thai-Cambodian
border) and ideally to eliminate P. falciparum malaria
strains altogether, by enhancing the active, passive and
individual follow-up surveillance system, and by ensur-
ing diagnosis and full radical treatment of all confirmed
malaria cases [11,12]. The Bureau of Vector-Borne
Diseases, Ministry of Public Health of Thailand has imple-
mented the containment project in seven provinces along
the Thai-Cambodian border, where artemisinin resistance
has been documented.
To boost the performance of the surveillance system,
which was essential for the project, the electronic
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aim was to replace existing paper-based malaria reporting
progressively. Web and mobile technologies were inte-
grated into the eMIS to enhance case detection at point-
of-care units, and index case investigation and active
follow-up of individual patients. Paper-based data were
computerized, and able to provide near real-time infor-
mation that was useful at both operational and manager-
ial levels to monitor case management in general and the
occurrence of resistant parasites in targeted provinces.
From data and information generated from the eMIS, this
study describes the pattern of response to artemisinin-
based treatment for falciparum malaria after three years
of project implementation in Thailand (2009–2011), and
discusses limitations of the innovative methods used.
Methods
Study sites
Under the Thailand malaria containment project, the
eMIS was developed and implemented in seven pro-
vinces along the Thai-Cambodian border (Figure 1). The
study site covered those places where emergence of
P. falciparum resistance to artemisinins has been docu-
mented (so-called zone 1), and areas where resistance
has not been reported but considered at high risk due to
being close to zone 1. In total, the study area covered 61
malaria posts and clinics, 27 vector-borne disease units,
and 11,615 villages with 12,508 hamlets, and about seven
million people. Malaria diagnosis and treatment were gen-
erally performed by malaria staff working at the malaria
posts and malaria clinics, under the direct supervision of
malaria teams operating at vector-borne disease units.
Patients with severe malaria were referred and managed at
district and referral hospitals. Rapid diagnostic tests were
used for all suspected malaria cases at point-of-care units.
Blood smears were also taken and sent to malaria clinics
and other upper levels to confirm diagnosis. Malaria treat-
ment was administered according to the national malaria
treatment guidelines. For uncomplicated P. falciparum in-
fection, three-day artesunate (total of 600 mg) and Meflo-
quine (total of 1,250 mg) plus primaquine (30 mg single
dose) were used as the first-line drugs. However, in zone
1, where artesunate resistance has been documented,
Atovaquone-proguanil (MalaroneW) was recommended on
direct observance (DOT) as the first-line drug to decrease
the pressure on artemisinins. Routine follow-up was usu-
ally conducted for all individual malaria cases, if possible,
to ensure patients’ compliance to treatment and monitor
the clinical and parasitological response eight times over a
period of at least 42 days.
Data collection
Data on the P. falciparum cases used in this study were
obtained from eMIS between January 2009 and December2011. Since eMIS became fully functional from July 2009,
malaria data reported between January and June 2009
were entered manually into eMIS. Data from eMIS were
double-checked with the existing paper-based records.
Details of the eMIS infrastructure are described else-
where [13]. Briefly, the development of eMIS was based
on the routine work of the malaria prevention and con-
trol programmed under the Bureau of Vector-borne
Diseases (BVBD), Ministry of Public Health, Thailand.
Data captured by eMIS were similar to the old paper-
based reporting system, but the redundancy of the data
was considerably reduced and the information workflow
was better harmonized, consolidated, and more access-
ible across units. According to the national malaria con-
trol programmed, the management of malaria cases
(diagnosis, treatment, and individual follow-up) was
generally performed at malaria posts and malaria clinics
at village level. Malaria case investigations were carried
out for each individual patient to determine the source
of infection, and the appropriateness of the measures
taken. Each individual case was followed up at home by
malaria staff or village malaria volunteers on days 1, 2, 3,
7, 14, 21, 28, and 42, to ensure clinical and parasito-
logical cure. Hospitalized patients were also followed up
after being discharged. Severe malaria is not common in
the area, so a very small proportion of malaria patients
were hospitalized. Active case detection was also per-
formed periodically. All information gathered from both
passive and active case detection, including case investi-
gations and follow-up visits, was entered into eMIS.
Data used in the analysis included demographic data,
such as gender, age, citizenship, if patients were Thai,
Migrant 1 (migrants staying in the area ≥6 months), or
Migrant 2 (migrants staying in the area <6 months). In
addition, time (year) and place where patients received
diagnosis and treatment were also used to describe the
spatial and temporal distribution of cases. Locations
where patients were diagnosed and treated were classi-
fied either by province or malaria-transmission area: per-
ennial transmission in A1 villages; periodic transmission
in A2; no transmission during the previous three years
but still at risk of malaria epidemic due to the presence
of vectors and a persistent suitable environment for mal-
aria transmission in B1 areas; and non-transmission
areas in B2 which, in principle, are not susceptible to
transmission. Parasitological data on day-0 (diagnosis)
and other follow-up days were categorized into either
positive or negative by malaria species without counting
parasites, since the data were based on actual routine
day-to-day field operations. In those circumstances, with
the number of records generated across provinces, espe-
cially in remote settings, it was considered difficult to
cross-check the accuracy and reliability of parasite count-
ing from all blood slides. Therefore, the data analysis does
Figure 1 Map of study area.
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common anti-malarial drug treatment promoted in the
containment area was MAS (mefloquine-artesunate com-
bination). MalaroneW was strictly recommended and used
in the three districts of zone 1 (in Chantaburi and Trat
provinces). Recommended second-line anti-malarial drugs
included quinine plus tetracycline or doxycycline.
This study used secondary data extracted from eMIS
databases with no identification linked to individualpatients. Official permission from the BVBD Director
was received before using the data for the final anal-
ysis. The study was reviewed and approved by the
Ethics Committee of the Faculty of Tropical Medicine,
Mahidol University.
Study population
To determine the response pattern of P. falciparum to
MAS, only falciparum malaria patients who received
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patient follow-up was recommended by the standard
protocol, lost at follow-up was still observed, due to field
constraints. The missing follow-ups may affect the
assessment of MAS cure rate, therefore, analysis of pa-
tient follow-up status was performed separately, i.e.
those who had fully completed parasitological follow-up
through days 3, 28, and 42, and those who had at least
one follow-up during the 42 days post-treatment (the
‘at least one follow-up’ group) (Figure 2). The number
of patients in each group was not mutually exclusive,
as patients could be classified into more than one.
For example, all patients who had completed 42-day
follow-up would fall into all groups (3-day, 28, 42, and
one follow-up group, at least).
Analytical methods
28-day and 42-day cure rate
The response to the MAS (cure rate) was determined
according to the WHO classification of responses to
treatment: as early treatment failure (ETF), late clinical
failure (LCF), and late parasitological failure (LPF) [10].
Only patients with adequate clinical and parasitological
response (ACPR) were classified as being cured. PCR
analysis is not performed to distinguish recrudescence
from re-infection in a very low transmission context where
re-infection is rare. The cure rates were calculated accord-
ing to patient follow-up status, to avoid possible bias due
to missing follow-up data. The 28-day cure rate was
assessed among patients with complete 28-day follow-up,












42-day cure rate 28-day cure rate
Figure 2 Data analysis scheme.Similarly, the 42-day cure rate was assessed in the
complete 42-day follow-up group, as well as in the ‘at least
one follow-up’ group. These cure rates were calculated
separately for each year during the three-year study period
to determine the trend of MAS response in this area.
Proportion of falciparum-positive patients during 42-day
follow-up
The proportion of patients who remained parasitaemic at
each follow-up day until day-42 was calculated, so as to de-
termine the actual pattern of falciparum response to MAS
within 42 days after the beginning of treatment. Analysis
was performed for each individual year so as to acquire a
yearly pattern of falciparum response to MAS. Mean pro-
portions of parasitaemic patients and 95% confidence inter-
vals (CIs) were estimated, to adjust for the heterogeneity of
expected “resistance level” across the seven provinces.
Measurement of the delayed parasite clearance time after MAS
The delayed parasite clearance time (PCT) was mea-
sured in patients who remained parasitaemic on day-3
after treatment [7,8]. Only patients who received MAS
and had fully completed follow-up between day-1 and
day-3 were included in the final PCT analysis. The over-
all proportion of patients with delayed parasite clearance
was then calculated. Relative risks and 95% CIs were
estimated to explore potential factors related to the
delayed parasite clearance, such as basic demographic
findings, years, and provinces where patients were
coming from. Because the delayed parasite clearance on
day-3 is considered as a proxy indicator for falciparumest in
9111
Others








clearance at day 3
28-day/42-day
cure rate
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with the re-appearance of the parasite later on during the
42 days follow-up. Therefore, the potential association be-
tween the delayed parasite clearance on day-3 and the re-
appearance of parasites between day-14 and day-42 was
also explored, bearing in mind that PCR was not used to
distinguish between recrudescence and re-infection.
Statistical analysis
The demographic characteristics of patients classified in
each group were described. Crude relative risks and 95% CIsTable 1 Demographic characteristic of Plasmodium falciparum
(until day-28 and day-42) and those with at least one follow-
Total Complete 42 da
N % N
Total 1174 100 578
Gender
Male 1067 91 520
Female 107 9 58
Age groups (years)
0-15 73 6 37
16-30 416 35 176
31-50 538 46 276
50+ 143 12 88
Fever on admission
Yes 72 6 61
No 10 1 8
Citizen
Thai 1024 87 529
Long-term Migrant 54 5 25
Short-term Migrant 96 8 24
Drug resistance area
A1 261 22 134
A2 221 19 89
B1 178 15 87
B2 514 44 268
Year
2009 706 60 379
2010 300 26 153
2011 168 14 46
Province
Buriram 13 1 10
Chantaburi 40 3 13
Sakaew 36 3 25
Srisaket 387 33 110
Surin 158 13 85
Trat 164 14 75for delayed parasite clearance time were estimated, using a
simple Poisson regression model (PROC GENMOD). All
statistical analysis was performed using SAS version 9.2
(Center of Excellence for Biomedical and Public Health
Informatics). Maps of the proportion of patients with
delayed parasite clearance time were generated using
ArcGIS version 10 (License:EFL647977001).
Results
From January 2009 to December 2011, a total of 9,111
malaria cases were confirmed and reported in thepatients, comparing those with complete follow-up
up, January 2009-December 2011
ys FU Complete 28 days FU ≥1 FU
% N % N %
49 619 53 967 82
90 561 91 880 91
10 58 9 87 9
6 40 6 59 6
30 193 31 343 35
48 294 47 437 45
15 91 15 126 13
11 63 10 68 7
1 8 1 10 1
92 568 92 863 89
4 25 4 49 5
4 26 4 55 6
23 145 23 215 22
15 94 15 192 20
15 94 15 137 14
46 286 46 423 44
66 401 65 576 60
26 167 27 265 27
8 51 8 126 13
2 10 2 10 1
2 13 2 17 2
4 25 4 31 3
19 114 18 297 31
15 107 17 126 13
13 77 12 152 16
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Chantaburi, Sakaew, Srisaket, Surin, Trat, and Ubon
Ratchathani). Of the malaria-infected patients, 1,709
(19%) were positive for P. falciparum. About 69%
(N= 1,174) of P. falciparum cases were treated with
MAS, and were therefore included in the study. Among
the 1,174 patients who received MAS, 967 (82%)
patients had at least one follow-up between day-1 and
day-42 (called ‘at least one follow-up’ group). In addition,
actual numbers of patients who completed follow-up
from day-1 until day-3, 28, and 42 were 651 (55%), 619
(53%), and 578 (49%) patients, respectively (Figure 2).
There was no gender difference between those with
complete follow-up and those with at least one follow-
up. Patients with a lack of follow-up were more likely to
be young adults (aged 16–30 years), were diagnosed in
2011, were living in Srisaket Province, or were either
short-term or long-term migrants and so had inconsist-
ent migratory patterns (Table 1).
Among cases with adequate follow-up, 90% were male
Thai citizens. Half of patients were adults aged between
31 and 50 years, and were resident in areas classified as
A1 (perennial transmission) and A2 (periodic transmis-
sion). Approximately 60% of patients were diagnosed in
the first year of the containment project, in 2009. Ubon
Ratchathani Province recorded the highest proportion of
falciparum cases (45%), since this province is the largest
and most populated (Table 1).
Cure rate of mefloquine-artesunate combination therapy
28-day cure rate
Overall, the 28-day cure rate of MAS in the area was above
90%. The decreasing trend in MAS cure rate over the three-
year period was not obviously observed, i.e., the cure rate
was 94% in 2001, 90% in 2010, 92% in 2009, and their 95%
CIs were overlapping each other. There was no difference in
cure rate among patients with complete 28-day follow-up
and those with at least one follow-up (Table 2).
42-day cure rate
The pattern of cure rate was similar for 28-day and 42-
day follow-up. The overall 42-day cure rate remainedTable 2 28-day and 42-day cure rates by year in seven provin
2009
N Cure %Cure N Cu
28 day cure rate
Complete FU 401 369 92.02 (89.37-94.67) 167 1
≥1 FU 576 526 91.32 (89.02-93.62) 265 2
42-day cure rate
Complete FU 379 349 92.08 (89.37-94.80) 153 1
≥1 FU 576 508 88.19 (85.56-90.83) 265 2above 90% over the whole three-year period; the year
2011 had the highest actual rate. There was no signifi-
cant difference in cure rate between those with complete
42-day follow-up and those with at least one follow-up
(Table 2).
Proportion of patients with parasites during 42-day
follow-up
Among patients under MAS with adequate 42-day fol-
low-up, parasites were cleared on day-3 in 87%, 83%,
and 87% respectively in 2009, 2010 and 2011. Only a few
patients (<1%) remained parasitaemic on day-7. How-
ever, parasite re-appearance during day-14 and day-42
was observed in about 5% of the patients. These patients
with reappearance of the parasite were re-treated and
monitored. Overall, all patients, except one in year 2009,
were parasite-free on day-42 after treatment. The
pattern of parasite clearance was relatively similar for
the complete 42-day follow-up group and the ‘at least
one follow-up’ group (Tables 3–4).
Figure 3 illustrates the pattern of parasite clearance
during 42-day follow-up over the three-year period. Num-
bers of parasite-positive patients reduced rapidly during
the first three days after treatment. The proportion of
patients with parasitaemia almost reached zero by day-7
and slightly increased between day-14 and day-42.
Delayed parasite clearance time (proportion of patients
still positive on day-3)
Among the 651 patients with adequate day-3 follow-up
who received ACT over the three-year project period, 94
patients (14%) were still parasitaemic on day-3 (Table 5).
There was no significant association between delayed
parasite clearance and gender, age group, or citizenship.
Patients living in seasonal transmission (A2) areas and
in Srisaket Province were respectively about three and
eight times more likely to have remaining parasites on
day-3 as compared to patients from perennial trans-
mission (A1) areas and other provinces. There was no
significant difference in the proportion of patients with
delayed parasite clearance time over the three-year
project period.ces, January 2009-December 2011
2010 2011
re %Cure N Cure %Cure
51 90.42 (85.96-94.88) 51 48 94.12 (83.76-98.77)
39 90.19 (86.61-93.77) 126 118 93.65 (89.39-97.91)
42 92.81 (88.72-96.90) 46 44 95.65 (85.16-99.47)
39 90.19 (86.61-93.77) 126 115 91.27 (86.34-96.20)
Table 3 Proportion of parasite-positive and 95% confidence interval (CI) by day of follow-up after anti-malarial
treatment in seven provinces along the Thai-Cambodian border in complete 42-day follow-up group, January 2009-
December 2011













Day 0 379 100 153 100.00 46 100.00
Day 1 151 39.84 (34.91-44.77) 94 61.44 (53.73-69.15) 28 63.04 (49.09-76.99)
Day 2 104 27.44 (22.95-31.93) 51 33.33 (25.86-40.80) 12 26.09 (13.40-38.78)
Day 3 49 12.93 (9.55-16.31) 26 16.99 (11.04-22.94) 6 13.04 (3.31-22.78)
Day 7 0 - 1 0.65 (0.02-3.59) 0 -
Day 14 3 0.79 (0.16-2.30) 0 - 0 -
Day 21 6 1.58 (0.33-2.84) 1 0.65 (0.02-3.59) 0 -
Day 28 8 2.11 (0.66-3.56) 1 0.65 (0.02-3.59) 1 2.17 (0.06-6.39)
Day 42 1 0.26 (0.01-1.46) 0 - 0 -
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used as a proxy measurement of falciparum resistance
to artemisinin derivatives. Further analysis was per-
formed to find out if those who had a delayed para-
site clearance time would be more likely to show
parasite re-appearance later on during the 42-day fol-
low-up. Results showed that only one patient tested
parasite-positive on day-7, indicating that MAS cleared
parasites on day-7 in almost all patients. However, some
patients (n = 35, 5%) had parasites reappearing between
day-14 and day-42 of treatment follow-up. Patients who
had parasite reappearance after day-14 were about twice
as likely to have delayed parasite clearance time, as com-
pared to those free of parasites throughout the entire
follow-up period. This association, however, was not
statistically significant.Table 4 Proportion of parasite-positive and 95% confidence i













Day 0 576 576 100 265 265
Day 1 419 173 41.29 (36.57-46.00) 180 112
Day 2 420 116 27.26 (23.34-31.90) 181 63
Day 3 420 57 13.57 (10.30-16.85) 179 32
Day 7 571 0 - 264 1
Day 14 417 5 1.20 (0.39-2.78) 172 0
Day 21 415 10 2.41 (0.93-3.89) 175 3
Day 28 559 10 1.79 (0.69-2.89) 256 6
Day 42 543 1 0.18 (0.00-1.02) 243 0Spatial and temporal distribution of patients with delayed
parasite clearance time
The proportion of patients with delayed parasite clear-
ance time varied across the seven provinces, showing a
similar spatial distribution over the three-year period
(Figure 4). Srisaket consistently reported the highest per-
centage of patients still parasite-positive on day-3; the
worst scenario was recorded in 2010, when approxi-
mately 42% of patients were still parasitaemic on day-3.
Discussion
The artemisinin resistance containment project started
in January 2009 as the result of growing evidence of
falciparum resistance to artemisinin on the Thai-
Cambodian border [8]. In this area, P. falciparum has
developed resistance to almost all anti-malarial drugsnterval (CI) by day of follow-up after anti-malarial












100 126 126 100
62.22 (55.14-69.30) 56 36 64.29 (51.74-76.84)
34.81 (27.87-41.75) 56 15 26.79 (15.19-38.38)
17.88 (12.26-23.49) 56 6 10.71 (2.61-18.82)
0.38 (0.01-2.09) 122 0 -
- 55 0 -
1.71 (0.35-4.93) 55 1 1.82 (0.05-9.72)
2.34 (0.49-4.20) 121 2 1.65 (0.20-5.84)





























a) Complete 42-day follow-up group
b) At least one follow-up group
Figure 3 Proportion of patients parasite-positive by day of follow-up in the year 2009 (solid), year 2010 (dashed), year 2011 (dotted),
for patients with complete 42-day follow-up (a) and those with at least one follow-up (b).
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arum resistance to artemisinins would not only limit
treatment options in border areas, but could comprom-
ise the management of uncomplicated malaria cases on
other continents, where ACT is widely recommended
and supported by international development partners.
Enhancing malaria surveillance was one of the major
tasks of the containment project to identify and respond
to suspected artemisinin-resistant cases. The project
monitored anti-malarial drug resistance, not only by
strengthening the use of routine data generated from the
surveillance system set up under the Thailand contain-
ment project, but also by strengthening (via extra staff
and incentives) individual follow-up of all falciparum-infected patients until day-28 or 42. The total population
in the seven provinces of Thailand along the Cambodian
border was targeted. A three-day course of mefloquine-
artesunate combination therapy (MAS) was used as
first-line treatment in the containment project area,
except in three districts bordering Cambodia, in Trat
and Chantaburi provinces, where artemisinin resistance
has been documented, leading to the choice of a non-
artemisinin drug instead of MAS3 [6].
The 28-day and 42-day cure rates of MAS observed in
this study were above 90% without PCR correction.
However, the situation of MAS resistance at this eastern
border of Thailand was more serious, as compared to
the north-western border of Thailand, where the efficacy
Table 5 Relative risk and 95% confidence interval (CI) of
potential risk factors for delayed parasite clearance on
day-3 after artesunate-mefloquine treatment, January
2009-November 2010
D3 Positive D3 Negative RR 95% CI
N % N %
Total 94 14 557 86
Gender
Female 8 14 51 86 1.00
Male 86 15 506 85 1.08 0.52-2.54
Age groups
0-15 3 7 39 93 1.00
16-30 31 15 176 85 2.29 0.77-9.87
31-50 48 16 258 84 2.42 0.83-10.28
50+ 12 13 82 87 1.90 0.57-8.70
Citizen
Thai 87 15 507 85 1.00
Long-term migrant 5 17 24 83 1.21 0.40-3.02
Short-term migrant 2 7 26 93 0.45 0.07-1.54
Drug resistance area
A1 14 9 134 91 1.00
A2 27 27 72 73 3.59* 1.80-7.45
B1 13 12 93 88 1.34 0.59-2.99
B2 40 13 258 87 1.48 0.80-2.91
Year
2009 56 13 361 87 1.00
2010 32 18 146 82 1.41 0.87-2.26
2011 6 11 50 89 0.77 0.29-1.76
Province
Buriram 0 0 10 100 -
Chantaburi 1 7 14 93 1.00
Sakaew 2 7 25 93 1.12 0.10-25.35
Srisaket 44 37 76 63 8.11* 1.55-149.29
Surin 22 18 99 82 3.11 0.58-57.82
Trat 15 19 66 81 3.18 0.57-59.85
Ubon Ratchathani 10 4 267 96 0.52 0.09-9.96
Reappearance
No 86 14 530 86 1.00
Yes 8 23 27 77 1.83 0.75-3.98
* Statistical significance.
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concern regarding the emergence of artemisinin resist-
ance in an area along the Thai-Myanmar border, espe-
cially among migrant workers [15].
Parasite re-appearance until day-42 was observed in
about 5% of patients. Since PCR confirmation was not
performed, parasites that were reappearing in thisroutine monitoring study could not be distinguished
either as a recrudescent infection due to drug resistance,
or re-infection from new parasites. A study carried out
in north-western Thailand from 1995 to 2007 reported
PCR-confirmed recrudescence in less than 5% of
patients under MAS [5,16]. Even if the results of this
study are not confirmed by PCR, the failure rate with
MAS observed during the study period remains less
than 10%.
Experience over the past decades has shown that arte-
misinin can rapidly reduce parasite load, clearing them
from blood generally after a two-day intake of treatment
[17]. However, in case of suspected P. falciparum resist-
ance to artemisinin, parasites are still observed in blood
longer than three days after treatment, which is called
“delayed parasite clearance time” [3]. Among patients
managed with MAS in this study, about 30% and 15%
still had parasitaemia on day-2 and day-3, respectively.
Almost all patients were parasite-free on day-7, with
about 2% showing parasite re-appearance during 28-day
follow-up. In Pailin, western Cambodia, percentages of
parasitaemic patients on day-2 and day-3 undergoing
artesunate monotherapy or mefloquine-artesunate treat-
ment were as high as 73% and 55%, respectively [7]. A
recent study with high-dose artesunate monotherapy
conducted in Battambang Province, western Cambodia,
also showed, after treatment, a relatively high proportion
of parasitaemic patients on day-2 and day-3 (48% on
day-2, and 22% on day-3) [18]. The proportion of
parasite-positive patients observed in the study area is
relatively high compared to other locations in western
Thailand and in Vietnam [5,19].
Unlike the resistance patterns of other anti-malarial
drugs, the results of clinical and in-vitro studies indi-
cated that artemisinin resistance is suspected by explor-
ing parasite clearance time rather than any sudden
change in therapeutic cure rate [7,9]. On the Thai-
Cambodian border, the WHO recommended using the
proportion of patients who remain parasitaemic on day-
3 as an indicator of suspected artemisinin resistance, to
be further confirmed by more sophisticated methods
[10]. In this area, delayed parasite clearance on day-3
was observed in about 14% of patients. Significant fac-
tors associated with delayed parasite clearance time were
people living in seasonal transmission areas or in
Srisaket Province, even though the confidence intervals
were quite large. The incidence of malaria in Srisaket
Province was dramatically increasing during the project
period, probably due to the border conflict between
Thailand and Cambodia affecting containment opera-
tions, with heavy movements of non-immune soldiers.
Currently, there is only one vector-borne disease unit
located in Srisaket Province with limited staff and
healthcare facilities. In addition to the relative
Figure 4 Distribution of delayed parasite clearance on day-3 after artesunate-mefloquine treatment by province, January 2009-
December 2011. Numbers in parentheses indicate number of total blood tests per province.
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http://www.malariajournal.com/content/11/1/300inaccessibility to healthcare and malaria services in con-
flict zones by residents, migrants and soldiers, the over-
all management of malaria control operations remains
difficult in this province, which might have resulted in
increasing transmission and, consequently, in the spread
of artemisinin-resistant parasites.
Some limitations have to be considered in this study.
The pattern of parasite clearance was presented as the
cumulative proportion of patients who remained parasi-
taemic by day after treatment. Parasite clearance curvethat shows reduction of parasite load by exploring
additional specific periods of time may provide more
information on parasite stage-specific response to arte-
misinins [17]. However, the parasite clearance graph pre-
sented here should be considered as a useful tool to
monitor parasite resistance in the routine surveillance
system, because it is difficult to obtain accurate parasite
examination and to count more often than once a day in
the field situation. Study results are also subject to bias
due to missing follow-up data (50%) and doubtful
Satimai et al. Malaria Journal 2012, 11:300 Page 12 of 13
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surveillance system. However, the results of this study
were similar, regardless of completion of follow-up data.
Additional research-based trials have to be designed
to further clarify or complement results such as these.
Even though the Ministry of Public Health had attempted
to enforce completion and a timely analysis of data
as much as possible, missing values were still observed.
Approximately 50% of falciparum patients had missing
parasitological data between day-1 and day-28 or day-42.
The profile of patients not able to be properly followed-
up was more likely to be a mobile population, such as
young adults and seasonal migrant workers. However, lit-
tle is known whether the resistance patterns of these two
groups are different from other populations. In this
study, regardless of missing data, the proportion of
delayed parasite clearance on day-3 in these two groups
was not significantly different from other age groups and
population types. In addition, missing data were mainly
(50%) observed in Srisaket Province in the conflict zone.
This province was also reported to be at high risk of
artemisinin resistance.
About 32% of overall falciparum malaria in this area
did not receive MAS treatment. These were a combin-
ation of patients who received other second-line drugs,
and others who had missing information on anti-
malarial drugs received. Since there are no commercial
anti-malarial drugs available in Thailand, those missing
drug information were likely to have received their
treatment in hospitals where standardized reporting
forms were not used and computerized, as in peri-
pheral malaria units. Unlike malaria patients who were
originally detected at malaria clinics/posts under BVBD
supervision, where patients’ details would be directly
recorded into eMIS, details of cases at local hospitals
were captured later into eMIS after admissions or treat-
ment. Malaria treatment provided at hospital could be
either first-line regimen (MAS), or second-line regimens
(quinine, tetracycline or doxycycline). Further improve-
ment in the reporting system is needed to assist data
sharing between hospitals and public health sectors.
In this study, the follow-up rate on day-42 was relatively
high (50%), considering constraints linked to field operation.
About 90% of patients who received complete follow-up on
day-7 were followed up on day-42. This allowed the study to
estimate a 42-day cure rate, which is recommended to be
long enough to monitor MAS resistance due to a long elim-
ination half-life of Mefloquine [4].
Conclusion
Plasmodium falciparum resistance to anti-malarial drugs
has always been a major threat in the region, and glo-
bally, in malaria control and elimination [14]. In areas
along the Thai-Cambodian border, resistance hasbeen reported to almost all anti-malarial drug classes,
justifying the policy shift to scale-up the use of more
efficacious and expensive combinations such as ACT,
to manage uncomplicated malaria infections [8,14].
Although the results of this study suggest that the thera-
peutic cure rate of mefloquine-artesunate combina-
tion therapy remains at an acceptable level, continuous
monitoring of P. falciparum resistance is critical in
this region.
Containment of parasites developing resistance to
anti-malarial drugs is one of the major goals supported
by countries and partners in the Mekong region, as well
as globally, to progress from malaria control towards
elimination. Malaria surveillance, with a focus on moni-
toring resistance, is critical to achieving such targets.
The electronic Malaria Information System (eMIS) has
been effectively set up and implemented to increase the
performance of the existing national surveillance system.
However, case detection at operational level and
data sharing between units and organizations remains a
day-to-day programmatic challenge, as maintaining the
system requires cross-checking computerized informa-
tion, then taking appropriate decisions.
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